[
  {
    "ts": null,
    "headline": "Horatio Alger Honor Puts ResMed Leadership And Growth Story In Focus",
    "summary": "ResMed founder Dr. Peter Farrell has received the Horatio Alger Award, recognizing his contributions to respiratory care and medical devices. The award highlights ResMed's role in addressing sleep apnea and other respiratory conditions through its therapies and digital health tools. This recognition brings added attention to NYSE:RMD at a time when the company’s share price is $257.61. For investors following NYSE:RMD, this award puts a spotlight on the company’s long-term presence in sleep...",
    "url": "https://finnhub.io/api/news?id=7b69a6ba714680f0b2a5c6e83b19761bf60fdaea55f493b4df87e5dc5c3bc352",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769756952,
      "headline": "Horatio Alger Honor Puts ResMed Leadership And Growth Story In Focus",
      "id": 138303602,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "ResMed founder Dr. Peter Farrell has received the Horatio Alger Award, recognizing his contributions to respiratory care and medical devices. The award highlights ResMed's role in addressing sleep apnea and other respiratory conditions through its therapies and digital health tools. This recognition brings added attention to NYSE:RMD at a time when the company’s share price is $257.61. For investors following NYSE:RMD, this award puts a spotlight on the company’s long-term presence in sleep...",
      "url": "https://finnhub.io/api/news?id=7b69a6ba714680f0b2a5c6e83b19761bf60fdaea55f493b4df87e5dc5c3bc352"
    }
  },
  {
    "ts": null,
    "headline": "ResMed Q2 Earnings Call Highlights",
    "summary": "ResMed (NYSE:RMD) executives highlighted revenue growth, margin expansion and continued investment in product development and demand-generation initiatives during the company’s second quarter fiscal 2026 earnings call. Management also discussed progress in its software portfolio, the company’s view",
    "url": "https://finnhub.io/api/news?id=ced6b8d87beb582f5c16c617c6b46ae47f54e4bd9798eb7b3f2e5083b3fd0cb5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769754987,
      "headline": "ResMed Q2 Earnings Call Highlights",
      "id": 138303603,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "ResMed (NYSE:RMD) executives highlighted revenue growth, margin expansion and continued investment in product development and demand-generation initiatives during the company’s second quarter fiscal 2026 earnings call. Management also discussed progress in its software portfolio, the company’s view",
      "url": "https://finnhub.io/api/news?id=ced6b8d87beb582f5c16c617c6b46ae47f54e4bd9798eb7b3f2e5083b3fd0cb5"
    }
  },
  {
    "ts": null,
    "headline": "RMD Q4 Deep Dive: Mask Innovation and Digital Health Expansion Drive Growth",
    "summary": "Medical device company ResMed (NYSE:RMD) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 11% year on year to $1.42 billion. Its non-GAAP profit of $2.81 per share was 3.2% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=d3835bca76c9e4d028012889c2843855b8f78779a61a3c70618b2557eb91a182",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769751197,
      "headline": "RMD Q4 Deep Dive: Mask Innovation and Digital Health Expansion Drive Growth",
      "id": 138310402,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "Medical device company ResMed (NYSE:RMD) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 11% year on year to $1.42 billion. Its non-GAAP profit of $2.81 per share was 3.2% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=d3835bca76c9e4d028012889c2843855b8f78779a61a3c70618b2557eb91a182"
    }
  },
  {
    "ts": null,
    "headline": "ResMed Inc (RMD) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations",
    "summary": "ResMed Inc (RMD) reports robust financial performance with 11% revenue growth and unveils new product launches amidst competitive market dynamics.",
    "url": "https://finnhub.io/api/news?id=63ffb05d619316276eb94d86d83d6efbd2f99efbdd1c1e0887f7f58c4f5349d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769749470,
      "headline": "ResMed Inc (RMD) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations",
      "id": 138303046,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "ResMed Inc (RMD) reports robust financial performance with 11% revenue growth and unveils new product launches amidst competitive market dynamics.",
      "url": "https://finnhub.io/api/news?id=63ffb05d619316276eb94d86d83d6efbd2f99efbdd1c1e0887f7f58c4f5349d2"
    }
  }
]